Current and future systemic treatments for renal cell carcinoma
- PMID: 22705280
- DOI: 10.1016/j.semcancer.2012.06.004
Current and future systemic treatments for renal cell carcinoma
Abstract
Systemic treatment of renal cell carcinoma has changed dramatically since 2007, with the development and approval of six new agents, which target complex molecular pathways regulating tumour angiogenesis and cell proliferation and survival. These treatments have significantly improved survival times in metastatic renal cell carcinoma, but remain palliative. A number of newer agents are in clinical development, which offer theoretical advantages over existing treatments, and research methodologies are adapting with the aim of defining an individualised approach to therapy which exploits the underlying tumour biology. This review will provide an overview of current and emerging systemic treatments and how they might be integrated with surgical therapy, with a particular focus on advanced, clear cell metastatic renal cell carcinoma.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Presurgical therapy in metastatic renal cell carcinoma.Expert Rev Anticancer Ther. 2007 Jan;7(1):73-8. doi: 10.1586/14737140.7.1.73. Expert Rev Anticancer Ther. 2007. PMID: 17187521 Review.
-
Neoadjuvant and adjuvant treatment of renal cell carcinoma.Expert Rev Anticancer Ther. 2012 Jun;12(6):765-76. doi: 10.1586/era.12.56. Expert Rev Anticancer Ther. 2012. PMID: 22716493 Review.
-
Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.Expert Rev Anticancer Ther. 2007 Dec;7(12):1749-61. doi: 10.1586/14737140.7.12.1749. Expert Rev Anticancer Ther. 2007. PMID: 18062749 Review.
-
Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.Eur Urol. 2010 Dec;58(6):819-28. doi: 10.1016/j.eururo.2010.08.029. Epub 2010 Aug 27. Eur Urol. 2010. PMID: 20828919 Review.
-
New targeted therapies for renal cell carcinoma.Expert Opin Investig Drugs. 2011 Jul;20(7):933-45. doi: 10.1517/13543784.2011.577065. Epub 2011 Apr 21. Expert Opin Investig Drugs. 2011. PMID: 21506895 Review.
Cited by
-
Importance and implications of exosomes in nephrology and urology.Pflugers Arch. 2023 Feb;475(2):153-166. doi: 10.1007/s00424-022-02771-y. Epub 2022 Nov 18. Pflugers Arch. 2023. PMID: 36399151 Free PMC article. Review.
-
[Renal cancer biomarkers. What is justified?].Pathologe. 2012 Nov;33 Suppl 2:278-81. doi: 10.1007/s00292-012-1683-8. Pathologe. 2012. PMID: 23052348 Review. German.
-
Expanding the miRNA Transcriptome of Human Kidney and Renal Cell Carcinoma.Int J Genomics. 2018 Jul 3;2018:6972397. doi: 10.1155/2018/6972397. eCollection 2018. Int J Genomics. 2018. PMID: 30057905 Free PMC article.
-
Quantitative proteomic analysis reveals sophisticated metabolic alteration and identifies FMNL1 as a prognostic marker in clear cell renal cell carcinoma.J Cancer. 2021 Sep 9;12(21):6563-6575. doi: 10.7150/jca.62309. eCollection 2021. J Cancer. 2021. PMID: 34659547 Free PMC article.
-
Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.Front Pharmacol. 2021 Dec 13;12:736860. doi: 10.3389/fphar.2021.736860. eCollection 2021. Front Pharmacol. 2021. PMID: 34966275 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical